Designed for Excellence in Nucleic Acid Production
BioSpring’s headquarters are in the heart of Europe, in Frankfurt, Germany, near the Frankfurt International Airport, ensuring easy access for international clients. Our facilities feature cutting-edge technology and state-of-the-art infrastructure, designed to meet the dynamic needs of our clients across the biotechnology and pharmaceutical industry. The care invested in designing, building, and maintaining our facilities reflects our dedication to manufacturing the high-quality APIs essential for developing breakthrough therapies.
Our network of facilities includes two fully operational sites, a third site in development, and a fourth site in the planning stages. These facilities feature robust capabilities for upstream and downstream processing, small-scale as well as large-scale, and quality control, ensuring we consistently deliver high-quality nucleic acid products.
BioSpring Site I
Fast Facts
Seven separate cGMP manufacturing cleanrooms
Nine analytical laboratories
Site I is equipped with seven separate cGMP manufacturing cleanrooms, complemented by specialized areas dedicated to synthesis and lyophilization.
Our clinical and commercial manufacturing cleanrooms support all synthesis scales, from small batch sizes for ultrarare and rare disease programs to large-scale, multi-kg batch sizes for high demand programs. Additionally, we have exclusive manufacturing areas for research-grade manufacturing, preclinical non-cGMP manufacturing, process development, process characterization, and diagnostic manufacturing.
Supporting our manufacturing operations are nine analytical laboratories, encompassing an area of 650 m² (~ 7,000 ft²). These laboratories are equipped with the latest analytical technologies, supporting all aspects of drug development including incoming QC, release and stability testing for API and drug product, and bioanalytical services.
BioSpring Site II
Fast Facts
Three independent cGMP cleanrooms
With the introduction of our second manufacturing site in 2023, we further expanded our manufacturing capacities. This expansion features three independent cGMP cleanrooms for oligonucleotide manufacturing to ensure clients get their clinical GMP material even faster.
Site II also includes dedicated cGMP mRNA manufacturing areas, equipped with the latest technology for IVT manufacturing. The new design leverages BioSpring's extensive experience in cGMP manufacturing and regulatory processes.
BioSpring Site III - Coming Soon
Fast Facts
Larger scales up to 2.5 mol
Larger batch sizes: up to 25 kg per lyophilized batch
We are excited to announce our biggest expansion to date! The completion of our third site in 2027, located in Offenbach, Germany. This sprawling, 15,800 m² (170,000 ft²) fully independent site will further expand manufacturing capacities and accommodate larger scales.Here’s what to expect at Site III:
New Infrastructure: Incorporating cutting-edge technologies to streamline operations.
New Warehouse: Expanding our storage capabilities to handle increased production volumes efficiently.
New High Volume Tank Farm: Enabling larger production scales with high-efficiency systems.
Optimized Production
Continuous Manufacturing: Implementing modern processes for increased productivity and consistent quality, enabling seamless batch production, reducing downtime, and enhancing output.
On Demand Fast Access to Additional Capacities: Ready-to-scale operations to meet growing capacity demands without delay.
BioSpring Campus - Future Launch
Following the completion of Site III, BioSpring plans to launch three new production modules. The new modular infrastructure will support continuous manufacturing on a larger scale with larger batch volumes. This significant capacity expansion aims to enhance throughput by enabling seamless manufacturing of multiple batches simultaneously.
